Leviev Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Biomater Sci. 2022 Nov 8;10(22):6486-6499. doi: 10.1039/d2bm01143c.
Transdermal drug delivery systems are a useful and minimally invasive alternative to other drug administration routes. Biodegradable polymeric microneedles (MNs) are widely used in controlled-release drug delivery due to their tunable properties and ease of patient self-administration. Polylactic--glycolic acid (PLGA) is often used for sustained drug release owing to special intrinsic properties including biocompatibility and biodegradability, which offer excellent applicability in preparing MNs. Congestive heart failure (CHF) is characterized by fluid overload during acute exacerbation, necessitating frequent patient hospitalization for continuous intravenous (i.v.) diuretic therapy. In the present study, we incorporated furosemide (FUR) as a model drug into flexible PLGA MN skin patches for potential intradermal delivery to overcome the limitations associated with i.v. diuresis. The MNs were fabricated by a casting-mold technique and consisted of two main parts, PLGA needle tips loaded with varying concentrations of FUR and a flexible backing layer comprising sodium alginate and glycerol. MN formulations were characterized by SEM and exhibited a uniform pyramidal shape. The measured surface pH of all samples suggested that no skin irritation is expected upon application. High encapsulation efficiency was obtained for FUR-MN formulations in which a decrease was noted as the FUR/PLGA ratio decreased. Drug loading content ranged from 19.1 ± 1% to 28.9 ± 1.4%. Successful insertion of MNs into a Parafilm® skin simulant model suggested that MNs will easily penetrate the skin's outermost layer, the , and will permit intradermal delivery of FUR. The MNs were further characterized by analytical methods. Finally, the MNs exhibited an initial burst release followed by a sustained release of FUR. Self-administered FUR-MNs can open new avenues to overcome i.v. drip limitations and increase patient compliance.
经皮给药系统是一种有用的、微创的替代其他给药途径的方法。可生物降解的聚合物微针(MNs)由于其可调的性质和易于患者自我给药而广泛用于控制释放药物递送。聚乳酸-羟基乙酸(PLGA)由于其特殊的固有特性,包括生物相容性和可生物降解性,常用于持续药物释放,在制备 MNs 方面具有极好的适用性。充血性心力衰竭(CHF)的特征是在急性加重期间液体超负荷,需要频繁住院进行持续静脉(i.v.)利尿剂治疗。在本研究中,我们将呋塞米(FUR)作为模型药物掺入柔性 PLGA MN 皮肤贴片中,用于潜在的皮内递药,以克服与 i.v. 利尿相关的限制。MNs 通过浇铸模具技术制造,由两部分组成,载有不同浓度 FUR 的 PLGA 针尖和由海藻酸钠和甘油组成的柔性背衬层。MN 制剂通过 SEM 进行了表征,表现出均匀的金字塔形状。所有样品的测量表面 pH 表明,应用时预计不会引起皮肤刺激。FUR-MN 制剂获得了高的包封效率,其中随着 FUR/PLGA 比例的降低而降低。药物载量范围为 19.1±1%至 28.9±1.4%。MN 成功插入 Parafilm®皮肤模拟模型中表明,MN 很容易穿透皮肤的最外层角质层,并允许 FUR 的皮内递药。MN 进一步通过分析方法进行了表征。最后,MN 表现出初始突释释放,随后是 FUR 的持续释放。自我管理的 FUR-MN 可以开辟新途径来克服 i.v. 滴注限制并提高患者依从性。